National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Infliximab (Remsima SC®), in combination with methotrexate, is indicated in rheumatoid arthritis for the reduction of signs and symptoms as well as the improvement in physical function in:

– Adult patients with active disease when the response to disease modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate.

– Adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.

 

NCPE Assessment Process Complete
Rapid review commissioned 04/03/2020
Rapid review completed 24/03/2020
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that infliximab SC not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.